Related Experiment Video
Updated: Jan 10, 2026
The Left Pneumonectomy Combined with Monocrotaline or Sugen as a Model of Pulmonary Hypertension in Rats
Published on: March 8, 2019
Sotatercept Improves Small Airway Disease and Hyperinflation in Patients with Pulmonary Hypertension
Hooman D Poor1,2, Jimmy Zhang1,2, Simone Hannah-Clark1,2
1Division of Pulmonary, Critical Care, and Sleep Medicine, Icahn School of Medicine at Mount Sinai, New York, NY.
Rationale:
Small airways disease (SAD) and hyperinflation are common in precapillary pulmonary hypertension (PH). Activin signaling plays an important role in airway and bronchial function.
Objective:
To determine whether treatment with sotatercept, an activin signaling inhibitor, for severe precapillary PH is associated with improvements in physiologic markers of SAD and hyperinflation.
Methods:
We conducted a single-center, retrospective cohort study of participants who received sotatercept for the treatment of severe precapillary PH despite background PH treatments who also had pulmonary function tests (PFT) before and after initiation of sotatercept treatment.
Measurements And Main Results:
Forty-eight participants were included (median age 68 years, 77% female). Median BMI was 26.7 kg/m2 (IQR 23.6-31.4). All participants were functional class III or IV. Follow-up PFTs obtained a median of 4.4 months after sotatercept initiation showed significant improvements: FEV1 +155 mL (11%, 95% confidence interval [CI], 100-215 mL; p<0.001), FVC +180 mL (10%, 95% CI, 125-245 mL; p<0.001), FEF25-75% +0.15 L/sec (16%, 95% CI, 0.03-0.28 L/sec; p=0.015), DLCO +0.79 mL/min/mmHg (10%, 95% CI, 0.30-1.25 mL/min/mmHg; p<0.01). In participants with paired lung volume measurements (n=22), RV decreased 210 mL (12%, 95% CI, -340 to -85 mL; p<0.01), RV/TLC decreased 5% (95% CI, -7% to -3%; p<0.001), and ERV increased 175 mL (29%, 95% CI, 50-385 mL; p=0.02). There was no overall change in TLC or FRC.
Conclusions:
In a real-world cohort of patients with severe precapillary PH from a variety of causes, sotatercept was associated with improvements in markers of SAD and hyperinflation.
Related Concept Videos
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
01:16Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
01:30Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...